Cancer Biology And Therapeutics: A Contemporary Review
Main Article Content
Abstract
Our understanding of the biology of cancer has advanced significantly during the latter part of the 20th century. Now that we have a better understanding of cancer at the genomic and epigenomic levels, we can identify the cell that initiates neoplastic transformation and understand the processes by which it invades other organs. With the use of this understanding, new medications that target certain molecules have been created, the immune system has been educated and tweaked to function more effectively, and ever-more potent treatment approaches have been created. However, the fight against cancer is still far from over, thus biomedical research in this field has to remain a top priority on a worldwide scale. Similarly, there is a need to enhance preventative initiatives and lessen disparate access to healthcare, particularly in nations with poor human development indices. Modern medical research continues to face significant challenges in the development of effective cancer therapy because of the intricate mechanisms behind carcinogenesis and tumor spread, as well as the drawbacks of the available cancer therapeutic choices. The application of nanotechnology in cancer therapies has great promise for enhancing cancer treatment outcomes. We could fully comprehend the pharmacological effects and investigate the mechanisms of the interaction between the nanomaterials with the help of information about the latest developments regarding cancer hallmarks. This could present opportunities for the development of mechanism-based Nano medicine to treat human cancers.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
C. E. DeSantis et al., “Cancer treatment and survivorship statistics, 2014,” CA. Cancer J. Clin., 2014, doi: 10.3322/caac.21235.
R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA. Cancer J. Clin., 2014, doi: 10.3322/caac.21208.
R. J. Gibson et al., “Systematic review of agents for the management of gastrointestinal mucositis in cancer patients,” Supportive Care in Cancer. 2013. doi: 10.1007/s00520-012-1644-z.
K. Jordan, R. Gralla, F. Jahn, and A. Molassiotis, “International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice,” European Journal of Pharmacology. 2014. doi: 10.1016/j.ejphar.2013.09.073.
K. McClellan et al., “Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors,” Cancers. 2022. doi: 10.3390/cancers14194769.
G. Gaudenzi, S. Carra, A. Dicitore, M. C. Cantone, L. Persani, and G. Vitale, “Fishing for neuroendocrine tumors,” Endocrine-Related Cancer. 2020. doi: 10.1530/ERC-19-0437.
World Health Organization, “World malaria report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.,” World Malar. Rep. 2017, 2017.
J. J. Ott, A. Ullrich, and A. B. Miller, “The importance of early symptom recognition in the context of early detection and cancer survival,” Eur. J. Cancer, 2009, doi: 10.1016/j.ejca.2009.08.009.
F. W. Gunz, “A look at cancer: The quality of life of cancer patients. Monograph series of the European Organization for Research and Treatment of Cancer,” Med. J. Aust., 1987, doi: 10.5694/j.1326-5377.1987.tb133469.x.
M. Švajdová and D. Ondruš, “Assessment of quality of life in patients with head and neck cancer,” Klin. Onkol., 2020, doi: 10.14735/amko2020195.
D. F. Cella and D. S. Tulsky, “Measuring quality of life today: methodological aspects.,” Oncology (Williston Park, N.Y.). 1990.
D. F. Cella and E. A. Cherin, “Quality of life during and after cancer treatment,” Comprehensive Therapy. 1988.
P. M. Fayers and D. R. Jones, “Measuring and analysing quality of life in cancer clinical trials: A review,” Stat. Med., 1983, doi: 10.1002/sim.4780020402.
M. E. Burkard et al., “Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board,” JCO Precis. Oncol., 2017, doi: 10.1200/po.16.00022.
W. B. Dalton et al., “Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board,” JCO Precis. Oncol., 2017, doi: 10.1200/po.16.00046.
P. Horak et al., “Precision oncology based on omics data: The NCT Heidelberg experience,” Int. J. Cancer, 2017, doi: 10.1002/ijc.30828.
A. Zehir et al., “Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients,” Nat. Med., 2017, doi: 10.1038/nm.4333.
R. Hoefflin et al., “Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience,” JCO Precis. Oncol., 2018, doi: 10.1200/po.18.00105.
L. Fass, “Imaging and cancer: A review,” Molecular Oncology. 2008. doi: 10.1016/j.molonc.2008.04.001.
F. L. Meyskens et al., “Cancer Prevention: Obstacles, Challenges, and the Road Ahead,” Journal of the National Cancer Institute. 2016. doi: 10.1093/jnci/djv309.
D. Schottenfeld and J. Beebe-Dimmer, “Alleviating the burden of cancer: A perspective on advances, challenges, and future directions,” Cancer Epidemiology Biomarkers and Prevention. 2006. doi: 10.1158/1055-9965.EPI-06-0603.
K. B. Tran et al., “The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019,” Lancet, 2022, doi: 10.1016/S0140-6736(22)01438-6.
J. Zhao et al., “Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019,” BMJ Oncol., 2023, doi: 10.1136/bmjonc-2023-000049.
D. McCloskey, “Other Things Equal - Economical Writing: An Executive Summary,” East. Econ. J., 1999.
J. Ferlay et al., “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012,” Int. J. Cancer, 2015, doi: 10.1002/ijc.29210.
H. Gelband et al., “Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: Key messages from Disease Control Priorities, 3rd edition,” The Lancet. 2016. doi: 10.1016/S0140-6736(15)00755-2.
M. Horneber, G. Bueschel, G. Dennert, D. Less, E. Ritter, and M. Zwahlen, “How many cancer patients use complementary and alternative medicine: A systematic review and metaanalysis,” Integrative Cancer Therapies. 2012. doi: 10.1177/1534735411423920.
World Health Organization, “WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants,” World Health, 2003.
F. Ahmed, A. Samantasinghar, A. M. Soomro, S. Kim, and K. H. Choi, “A systematic review of computational approaches to understand cancer biology for informed drug repurposing,” Journal of Biomedical Informatics. 2023. doi: 10.1016/j.jbi.2023.104373.
T. M. Errington, E. Iorns, W. Gunn, F. E. lisabet. Tan, J. Lomax, and B. A. Nosek, “An open investigation of the reproducibility of cancer biology research,” Elife, 2014, doi: 10.7554/eLife.04333.
A. Katti, B. J. Diaz, C. M. Caragine, N. E. Sanjana, and L. E. Dow, “CRISPR in cancer biology and therapy,” Nature Reviews Cancer. 2022. doi: 10.1038/s41568-022-00441-w.
H. Takeshima and T. Ushijima, “Accumulation of genetic and epigenetic alterations in normal cells and cancer risk,” npj Precision Oncology. 2019. doi: 10.1038/s41698-019-0079-0.
G. Fiscon, F. Conte, L. Farina, and P. Paci, “Network-based approaches to explore complex biological systems towards network medicine,” Genes. 2018. doi: 10.3390/genes9090437.
S. Jin et al., “A network-based approach to uncover microRNA-mediated disease comorbidities and potential pathobiological implications,” npj Syst. Biol. Appl., 2019, doi: 10.1038/s41540-019-0115-2.
E. Galan-Vasquez and E. Perez-Rueda, “A landscape for drug-target interactions based on network analysis,” PLoS One, 2021, doi: 10.1371/journal.pone.0247018.
Y. Feng, Q. Wang, and T. Wang, “Drug Target Protein-Protein Interaction Networks: A Systematic Perspective,” BioMed Research International. 2017. doi: 10.1155/2017/1289259.
H. Liu, W. Zhang, L. Nie, X. Ding, J. Luo, and L. Zou, “Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network,” BMC Bioinformatics, 2019, doi: 10.1186/s12859-019-3288-1.
J. Lin et al., “Targeting peptide-mediated interactions in omics,” Proteomics. 2023. doi: 10.1002/pmic.202200175.
S. Ruijtenberg and S. van den Heuvel, “Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression,” Cell Cycle. 2016. doi: 10.1080/15384101.2015.1120925.
M. Jiang, S. Xu, M. Bai, and A. Zhang, “The emerging role of meis1 in cell proliferation and differentiation,” American Journal of Physiology - Cell Physiology. 2021. doi: 10.1152/AJPCELL.00422.2020.
A. A. Dayem, S. Bin Lee, and S. G. Cho, “The impact of metallic nanoparticles on stem cell proliferation and differentiation,” Nanomaterials. 2018. doi: 10.3390/nano8100761.
S. Murakami and H. Motohashi, “Roles of Nrf2 in cell proliferation and differentiation,” Free Radical Biology and Medicine. 2015. doi: 10.1016/j.freeradbiomed.2015.06.030.
M. Agathocleous and W. A. Harris, “Metabolism in physiological cell proliferation and differentiation,” Trends in Cell Biology. 2013. doi: 10.1016/j.tcb.2013.05.004.
S. Wan et al., “mTORC1 signaling pathway integrates estrogen and growth factor to coordinate vaginal epithelial cells proliferation and differentiation,” Cell Death Dis., 2022, doi: 10.1038/s41419-022-05293-8.
D. J. Zabransky, E. M. Jaffee, and A. T. Weeraratna, “Shared genetic and epigenetic changes link aging and cancer,” Trends in Cell Biology. 2022. doi: 10.1016/j.tcb.2022.01.004.
J. Wen, J. Fu, W. Zhang, and M. Guo, “Genetic and epigenetic changes in lung carcinoma and their clinical implications,” Modern Pathology. 2011. doi: 10.1038/modpathol.2011.46.
B. Qi et al., “Generality and characteristics of genetic and epigenetic changes in newly synthesized allotetraploid wheat lines,” J. Genet. Genomics, 2010, doi: 10.1016/S1673-8527(09)60091-6.
D. Liu et al., “Spatial Multiomics Analysis Reveals Only Minor Genetic and Epigenetic Changes in Human Liver Cancer Stem-Like Cells Compared With Other Tumor Parenchymal Cells,” Front. Cell Dev. Biol., 2022, doi: 10.3389/fcell.2022.810687.
B. P. Balaton and C. J. Brown, “Contribution of genetic and epigenetic changes to escape from X-chromosome inactivation,” Epigenetics and Chromatin, 2021, doi: 10.1186/s13072-021-00404-9.
R. Bobadilla Landey et al., “Assessment of genetic and epigenetic changes during cell culture ageing and relations with somaclonal variation in Coffea arabica,” Plant Cell. Tissue Organ Cult., 2015, doi: 10.1007/s11240-015-0772-9.
S. Gerstberger, Q. Jiang, and K. Ganesh, “Metastasis,” Cell. 2023. doi: 10.1016/j.cell.2023.03.003.
F. Macedo et al., “Bone metastases: An overview,” Oncol. Rev., 2017, doi: 10.4081/oncol.2017.321.
M. Park, D. Kim, S. Ko, A. Kim, K. Mo, and H. Yoon, “Breast Cancer Metastasis: Mechanisms and Therapeutic Implications,” International Journal of Molecular Sciences. 2022. doi: 10.3390/ijms23126806.
J. Kubik and K. Pawlak, “Epithelial-mesenchymal transition,” Curr. Issues Pharm. Med. Sci., 2023, doi: 10.2478/cipms-2023-0005.
V. Graziani, I. Rodriguez-Hernandez, O. Maiques, and V. Sanz-Moreno, “The amoeboid state as part of the epithelial-to-mesenchymal transition programme,” Trends in Cell Biology. 2022. doi: 10.1016/j.tcb.2021.10.004.
Y. Zhang and R. A. Weinberg, “Epithelial-to-mesenchymal transition in cancer: complexity and opportunities,” Frontiers of Medicine. 2018. doi: 10.1007/s11684-018-0656-6.
P. Donizy et al., “Merkel cell carcinoma of unknown primary: Immunohistochemical and molecular analyses reveal distinct UV-signature/MCPyV-negative and high immunogenicity/MCPyV-positive profiles,” Cancers (Basel)., 2021, doi: 10.3390/cancers13071621.
K. Ganesh et al., “L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer,” Nat. Cancer, 2020, doi: 10.1038/s43018-019-0006-x.
D. Cao et al., “A new tumorsphere culture condition restores potentials of self-renewal and metastasis of primary neuroblastoma in a mouse neuroblastoma model,” PLoS One, 2014, doi: 10.1371/journal.pone.0086813.
T. N. Seyfried and L. C. Huysentruyt, “On the origin of cancer metastasis,” Crit. Rev. Oncog., 2013, doi: 10.1615/CritRevOncog.v18.i1-2.40.
Q. Guo et al., “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy,” Journal of Immunology Research. 2016. doi: 10.1155/2016/9720912.
G. Mahlbacher, L. T. Curtis, J. Lowengrub, and H. B. Frieboes, “Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment,” J. Immunother. Cancer, 2018, doi: 10.1186/s40425-017-0313-7.
S. Sangaletti, R. Ferrara, C. Tripodo, M. C. Garassino, and M. P. Colombo, “Myeloid cell heterogeneity in lung cancer: implication for immunotherapy,” Cancer Immunology, Immunotherapy. 2021. doi: 10.1007/s00262-021-02916-5.
D. Yang, R. Moniruzzaman, H. Wang, H. Wang, and Y. Chen, “Cross-Dataset Single-Cell Analysis Identifies Temporal Alterations in Cell Populations of Primary Pancreatic Tumor and Liver Metastasis,” Cancers (Basel)., 2023, doi: 10.3390/cancers15082396.
Z. Zhou and M. Li, “Targeted therapies for cancer,” BMC Medicine. 2022. doi: 10.1186/s12916-022-02287-3.
Y. T. Lee, Y. J. Tan, and C. E. Oon, “Molecular targeted therapy: Treating cancer with specificity,” European Journal of Pharmacology. 2018. doi: 10.1016/j.ejphar.2018.07.034.
S. Lheureux, C. Denoyelle, P. S. Ohashi, J. S. De Bono, and F. M. Mottaghy, “Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician,” European Journal of Nuclear Medicine and Molecular Imaging. 2017. doi: 10.1007/s00259-017-3695-3.
Q. Wu, W. Wu, V. Jacevic, T. C. C. Franca, X. Wang, and K. Kuca, “Selective inhibitors for JNK signalling: a potential targeted therapy in cancer,” Journal of Enzyme Inhibition and Medicinal Chemistry. 2020. doi: 10.1080/14756366.2020.1720013.
K. Augoff, A. Hryniewicz-Jankowska, R. Tabola, and K. Stach, “MMP9: A Tough Target for Targeted Therapy for Cancer,” Cancers. 2022. doi: 10.3390/cancers14071847.
S. Montoya, D. Soong, N. Nguyen, M. Affer, S. P. Munamarty, and J. Taylor, “Targeted therapies in cancer: To be or not to be, selective,” Biomedicines. 2021. doi: 10.3390/biomedicines9111591.
H. Zhang et al., “Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer,” Molecular Cancer. 2021. doi: 10.1186/s12943-021-01431-6.
D. Zhang et al., “Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy,” Nat. Nanotechnol., 2022, doi: 10.1038/s41565-022-01122-3.
B. M. Hussen et al., “Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges,” Military Medical Research. 2023. doi: 10.1186/s40779-023-00468-6.
V. Karn et al., “CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope,” Cancer Cell International. 2022. doi: 10.1186/s12935-022-02654-3.
B. Zhang, S. R. Birer, M. Dvorkin, J. Shruti, and L. Byers, “New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?,” Am. Soc. Clin. Oncol. Educ. B., 2021, doi: 10.1200/edbk_320673.
B. H. Diamond, U. C. Shukla, M. H. Sueyoshi, and K. E. Huber, “Radiation Oncology,” in The History of Maxillofacial Surgery: An Evidence-Based Journey, 2022. doi: 10.1007/978-3-030-89563-1_14.
A. Khajeali, R. Khodadadi, and J. Pirayesh Islamian, “Metal-based nanoparticles in gastric cancer radiotherapy,” Journal of Drug Delivery Science and Technology. 2020. doi: 10.1016/j.jddst.2020.101576.
Y. H. Peng, S. A. Richard, Z. Lan, and Y. Zhang, “Radiation induced glioma in a sexagenarian: A case report,” Med. (United States), 2021, doi: 10.1097/MD.0000000000025373.
L. Chang et al., “Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance,” Critical Reviews in Oncology/Hematology. 2015. doi: 10.1016/j.critrevonc.2015.07.005.
L. Delclos and J. P. Smith, “Ovarian cancer, with special regard to types of radiotherapy,” Natl. Cancer Inst. Monogr., 1975.
J. M. Van Nguyen et al., “Risk of second malignancy in patients with ovarian clear cell carcinoma,” Int. J. Gynecol. Cancer, 2021, doi: 10.1136/ijgc-2020-001946.
L. W. Brady, B. Micaily, C. T. Miyamoto, J. I. Keit, and G. B. Mieszkalski, “Therapeutic advances in radiologic treatment of cancer,” Cancer, 1993, doi: 10.1002/1097-0142(19931201)72:11+<3463::AID-CNCR2820721613>3.0.CO;2-W.
J. F. Fowler, “The radiobiology of prostate cancer including new aspects of fractionated radiotherapy,” in Acta Oncologica, 2005. doi: 10.1080/02841860410002824.
B. L. Madsen, R. A. Hsi, H. T. Pham, J. F. Fowler, L. Esagui, and J. Corman, “Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results,” Int. J. Radiat. Oncol. Biol. Phys., 2007, doi: 10.1016/j.ijrobp.2006.10.050.
K. Wink et al., “Particle therapy for non-small cell lung tumors: Where do we stand? A systematic review of the literature,” Frontiers in Oncology. 2014. doi: 10.3389/fonc.2014.00292.
J. M. Slater, J. O. Archambeau, D. W. Miller, M. I. Notarus, W. Preston, and J. D. Slater, “The proton treatment center at Loma Linda University Medical Center: Rationale for and description of its development,” Int. J. Radiat. Oncol. Biol. Phys., 1992, doi: 10.1016/0360-3016(92)90058-P.
H. Liu and J. Y. Chang, “Proton therapy in clinical practice,” Chinese Journal of Cancer. 2011. doi: 10.5732/cjc.010.10529.
Y. Cao, C. L. Tseng, J. M. Balter, F. Teng, H. A. Parmar, and A. Sahgal, “Mr-guided radiation therapy: Transformative technology and its role in the central nervous system,” Neuro-Oncology. 2017. doi: 10.1093/neuonc/nox006.
S. Ali et al., “Quality Standards and Pharmacological Interventions of Natural Oils : Current Scenario and Future Perspectives,” 2023, doi: 10.1021/acsomega.3c05241.
S. Ali et al., “A Brief Review Of Pathophysiology And Management Of Different Types Of Arthritis,” vol. 12, no. 12, pp. 199–230, 2023, doi: 10.48047/ecb/2023.12.si12.016.
J. Y. Chang et al., “Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials,” Lancet Oncol., 2015, doi: 10.1016/S1470-2045(15)70168-3.
C. G. Rusthoven, B. D. Kavanagh, and S. D. Karam, “Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): Addressing the fallout of disruptive randomized data,” Ann. Transl. Med., 2015, doi: 10.3978/j.issn.2305-5839.2015.06.15.
S. M. Shirvani et al., “Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly,” JAMA Surg., 2014, doi: 10.1001/jamasurg.2014.556.
S. M. Shirvani, J. Y. Chang, and J. A. Roth, “Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery?,” Thoracic Surgery Clinics. 2013. doi: 10.1016/j.thorsurg.2013.05.009.